AVIR vs SIGA
AVIR: A clinical-stage antiviral company advancing pan-genotypic HCV and HEV therapies toward FDA submissions, leveraging proprietary nucleoside/nucleotide chemistry for differentiated viral treatment regimens. SIGA: SIGA is a biodefense-focused pharmaceutical company selling tecovirimat (TPOXX®), an FDA-approved smallpox antiviral, primarily to the U.S. Strategic National Stockpile and international governments.
Side-by-side fundamentals
| Metric | AVIR | SIGA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.81 | $3.39 | |
| Market cap as of 2026-07-23 | $385M | $242M | |
| P/E as of 2026-07-23 | n/a | 11.96 | |
| PEG as of 2026-07-23 | -0.08 | n/a | |
| Net margin as of 2026-07-23 | +34.5% | +21.6% | AVIR higher |
| Gross margin as of 2026-07-23 | n/a | +65.4% | |
| Operating margin as of 2026-07-23 | +39.4% | +22.0% | AVIR higher |
| ROE as of 2026-07-23 | -57.0% | +10.6% | SIGA higher |
| ROA as of 2026-07-23 | -51.5% | +8.9% | SIGA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -22.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -5.1% | |
| Dividend yield as of 2026-07-23 | n/a | +17.9% | |
| Dividend streak (yrs) SEC XBRL | n/a | 4 | |
| Beta as of 2026-07-23 | 0.27 | 0.91 | |
| 1-year return as of 2026-07-22 close | +42.0% | -47.7% | AVIR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.